MERRILL LYNCH STRATEGIC RET. NOTES - OIL&NATURAL GAS 3/28/07

OGN

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN) today announced its results for the third quarter ended September 30, 2025. “I am humbled to be working alongside our talented team during this pivotal time for Organon,” said Joe Morrissey, Organon's Interim Chief Executive Officer. “We are harnessing the company's many strengths, including a diverse portfolio that we expect will generate more than $900 million in free cash flow before one-time costs this year. We also remain committed to.

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon divests the JADA System for up to $465 Million to Laborie.

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon to announce Q3 2025 financial results on November 10, 2025.

Organon & Co. shares plunged Monday, October 27th, after CEO Kevin Ali resigned amid an audit committee investigation into wholesaler sales irregularities. Despite the scandal, OGN's valuation at $7 per share is extremely cheap compared to peers, with a diversified product portfolio and global reach. The main risk is OGN's heavy $8.3 billion net debt load, which could hinder share price recovery if revenue growth remains sluggish.

SAN FRANCISCO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- On October 27, 2025, investors in Organon & Co. (NYSE: OGN) saw the price of their shares plummet $2.10 (-23%) after the company announced the findings of its Audit Committee's investigation into improper wholesale sales practices for Nexplanon and CEO Kevin Ali's resignation.

Organon said on Monday CEO Kevin Ali will resign from his role and be replaced by Joseph Morrissey on an interim basis, after an internal investigation into wholesaler sales practices for its Nexplanon contraceptive implant.

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN) (“Organon” or “the company”) today announced that its Board of Directors has appointed the Company's Executive Vice President and Head of Manufacturing & Supply, Joseph Morrissey, Interim Chief Executive Officer. Board Chair Carrie S. Cox will also take on additional responsibilities on an interim basis as Executive Chair to support Mr. Morrissey in his new role. Director Robert Essner will assume the role of Lead Independent Director.

The latest trading day saw Organon (OGN) settling at $9.05, representing a +1.23% change from its previous close.

Organon (OGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.